FIELD: medicine.
SUBSTANCE: invention refers to medicine, particularly pulmonology, laboratory diagnostics and immunology, and can be used for treating bronchial asthma. That is ensured by evaluating a bronchial asthma control level by GINA 2006 criteria and a related therapeutic stage; additionally, patient's peripheral blood is examined for CD 25+ antigen expressed on an membrane of activated lymphocytes by indirect immunofluorescence test, and if the CD 25+ cell level is 11 or more, then the combined therapy with iGCS and long-acting β2-antagonist is recommended.
EFFECT: method ensured bronchial asthma control ensured by reflected effectiveness of the basic anti-inflammatory therapy.
1 ex, 1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF ESTIMATING ANTIASTHMATIC THERAPY EFFICIENCY | 2010 |
|
RU2439570C2 |
| METHOD OF DETERMINING BRONCHIAL ASTHMA CONTROL RATIO | 2010 |
|
RU2422827C1 |
| METHOD OF DETERMINING BRONCHIAL ASTHMA CONTROL RATIO | 2010 |
|
RU2440035C2 |
| METHOD OF MEDICAL REHABILITATION OF PATIENTS WITH PARTIALLY CONTROLLED MILD BRONCHIAL ASTHMA | 2017 |
|
RU2655543C1 |
| METHOD OF PREVENTING DEVELOPMENT OF UNCONTROLLED BRONCHIAL ASTHMA FORMS INDUCED BY MANGANESE AND VANADIUM IMPACT IN CHILDREN OVER 5 YEARS OLD | 2014 |
|
RU2555341C1 |
| METHOD FOR PREVENTING PARTIALLY CONTROLLED BRONCHIAL ASTHMA CAUSED BY MANGANESE AND VANADIUM EXPOSURE IN CHILDREN AGED 5 AND OLDER | 2014 |
|
RU2546525C1 |
| METHOD OF ACHIEVING CONTROL OVER BRONCHIAL ASTHMA | 2013 |
|
RU2571894C2 |
| METHOD FOR PREDICTING INSTABLE CLINICAL COURSE OF BRONCHIAL ASTHMA | 2004 |
|
RU2262891C1 |
| METHOD OF TREATING PATIENTS WITH BRONCHIAL ASTHMA | 2008 |
|
RU2383345C1 |
| METHOD OF PREDICTING RISK OF DEVELOPMENT OF THERAPEUTIC RESISTANCE IN PATIENTS WITH BRONCHIAL ASTHMA | 2010 |
|
RU2433401C1 |
